Thus, inhibition of EGFR signaling by monoclonal antibodies (i.e., Cetuximab) or tyrosine kinase inhibitors (TKi; i.e., gefitinib or erlotinib) is synergistic with BRAF inhibition in colon carcinoma cells [9]. The gene discussed is EGFR; the disease is colon carcinoma.